Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077091 | 0.96 | KAT2B (0.41) | KAT2BBAZ2BL3MBTL1CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL27781343 | 0.93 | KAT2B (0.40) | KAT2BBAZ2BL3MBTL1CHRM2CHRM4 | |
| SCHEMBL28586197 | 0.83 | CYP19A1 (0.40) | KAT2BBAZ2BL3MBTL1EPHX1CHRM2 | |
| SCHEMBL836642 | 0.83 | — | — | |
| SCHEMBL2603677 | 0.83 | — | — | |
| SCHEMBL8224670 | 0.83 | — | — | |
| SCHEMBL23506964 | 0.81 | EPHX1 (0.52) | EPHX1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL1695496 | 0.81 | EPHX1 (0.52) | EPHX1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL200090 | 0.81 | EPHX1 (0.52) | EPHX1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL22540554 | 0.81 | EPHX1 (0.52) | EPHX1CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | IDENIX PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | claimed |
| WO-2007025043-A2 | SEVEN-MEMBERED RING NUCLEOSIDES | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | NSUN2, NSUN3, HAVCR2 | KAT2B 4206/4885BAZ2B 1118/4885L3MBTL1 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.